<![CDATA[
The Landscape of ME/CFS Treatment Is Changing
For decades, patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) were told that no effective treatments existed — that the best they could hope for was symptom management and psychological support. That era is ending. A convergence of new research, clinical trials, and therapeutic innovation is reshaping how we understand and treat this debilitating condition.
At St. George Hospital in Bad Aibling, Germany, Dr. Julian Douwes and our medical team have been treating ME/CFS patients with integrative protocols for over three decades. We closely monitor emerging research to ensure our patients have access to the most promising and evidence-informed therapies available. Here is what the science tells us as of 2025.
IHHT: Mitochondrial Rehabilitation Through Altitude Training
Interval Hypoxia-Hyperoxia Training (IHHT) has emerged as one of the most compelling therapeutic options for ME/CFS patients. The principle is elegant: by alternating periods of reduced oxygen (simulating altitude) and enriched oxygen delivery while the patient rests comfortably, IHHT triggers two critical cellular processes:
- Mitophagy: The selective removal of damaged, dysfunctional mitochondria
- Mitochondrial biogenesis: The production of new, efficient mitochondria
A growing body of research supports the use of IHHT for conditions characterized by mitochondrial dysfunction. A 2021 review in the International Journal of Molecular Sciences concluded that intermittent hypoxia training improves mitochondrial function, reduces oxidative stress, and enhances exercise tolerance (Serebrovska et al., 2021).
At St. George Hospital, IHHT is a cornerstone of our chronic fatigue program. Patients typically undergo 10 to 15 sessions over a two-week inpatient stay. Many report noticeable improvements in energy, cognitive clarity, and exercise tolerance during the treatment course, with continued improvement over the following months.
Therapeutic Apheresis: Removing Pathological Factors from the Blood
Therapeutic apheresis — the selective filtering and removal of specific blood components — has gained significant attention in the ME/CFS research community. The rationale is based on the discovery that ME/CFS patients often have elevated levels of autoantibodies, inflammatory cytokines, and other pathological factors circulating in their blood.
Key Research Developments
- Autoantibody removal: Studies by Scheibenbogen and colleagues at Charité Berlin have identified autoantibodies against G-protein-coupled receptors (GPCR-AABs) in a significant subset of ME/CFS patients. Immunoadsorption — a form of apheresis — has shown promising results in reducing symptom burden in patients with elevated autoantibody titers.
- BC007 (Berliner Cures): This investigational aptamer-based drug targets GPCR autoantibodies and has shown encouraging preliminary results in both ME/CFS and post-COVID patients. Clinical trials are ongoing as of 2025, and the compound represents a potentially targeted approach to autoimmune-driven fatigue.
At St. George Hospital, we utilize therapeutic apheresis as part of our comprehensive treatment protocols for patients with documented autoantibody elevation or inflammatory blood markers. Apheresis is performed under medical supervision in our inpatient setting.
NAD+ Intravenous Therapy: Restoring Cellular Energy Currency
Nicotinamide adenine dinucleotide (NAD+) is essential for mitochondrial energy production, DNA repair, and cellular signaling. Research has consistently shown that NAD+ levels decline with age and are often significantly depleted in ME/CFS patients.
Intravenous NAD+ therapy delivers this critical molecule directly into the bloodstream, bypassing the limitations of oral supplementation. Clinical observations suggest benefits including:
- Improved mitochondrial ATP production
- Enhanced cognitive function and reduced brain fog
- Better sleep quality
- Increased physical stamina
While large-scale randomized controlled trials are still needed, the biological rationale is strong, and clinical experience at specialized centers — including St. George Hospital — consistently shows patient-reported improvements.
Peptide Therapies: An Emerging Frontier
Peptide therapy represents one of the more innovative — and investigational — approaches being explored for ME/CFS. Specific peptides under investigation include:
- BPC-157: A gastric pentadecapeptide with anti-inflammatory and tissue-repair properties
- Thymosin Alpha 1: An immune-modulating peptide that enhances NK cell and T-cell function
- KPV: An anti-inflammatory tripeptide derived from alpha-MSH
Important note: Peptide therapies for ME/CFS remain investigational. They are not approved as standard treatments for this condition, and clinical trial data is limited. At St. George Hospital, we discuss peptide options with patients on an individual basis, with full transparency about the current evidence level and investigational status of these compounds.
Ozone Therapy: Modulating Immunity and Oxygen Utilization
Medical ozone therapy, delivered as major autohemotherapy (MAH), continues to show relevance for ME/CFS treatment. The mechanism involves controlled oxidative stress that upregulates the body’s own antioxidant systems (Nrf2 pathway), improves red blood cell oxygen delivery, and modulates immune function.
A 2020 systematic review found evidence supporting ozone therapy’s anti-inflammatory and immunomodulatory effects, particularly relevant for conditions involving chronic immune activation (Scassellati et al., 2020).
Neurofeedback and Neuromodulation
The neurological symptoms of ME/CFS — brain fog, unrefreshing sleep, autonomic dysfunction, and hypersensitivity — are increasingly recognized as central features of the disease rather than secondary complaints. Neurofeedback therapy addresses these symptoms by training the brain’s electrical patterns toward healthier configurations.
Emerging research into vagus nerve stimulation (VNS) — both invasive and non-invasive — also shows promise for ME/CFS, particularly for autonomic dysregulation and neuroinflammation. Transcutaneous VNS devices are being evaluated in clinical trials as of 2025.
Clinical Trials to Watch in 2025
Several important clinical trials are underway or recently completed that may shape the future of ME/CFS treatment:
| Trial/Compound | Mechanism | Status (2025) |
|---|---|---|
| BC007 (Berliner Cures) | GPCR autoantibody neutralization | Phase II trials ongoing |
| Low-dose naltrexone (LDN) | Immune modulation, glial cell inhibition | Multiple small trials; growing clinical use |
| Rituximab (re-evaluation) | B-cell depletion | Earlier Phase III failed; mechanism subgroup analysis continues |
| Oxaloacetate | Metabolic support, NAD+/NADH ratio | Small clinical trial results published |
| Transcutaneous vagus nerve stimulation | Autonomic and immune regulation | Multiple trials in progress |
Our Integrative Approach: Combining the Most Promising Therapies
At St. George Hospital, we do not wait for a single “breakthrough drug” to treat ME/CFS. Instead, we combine the most evidence-informed therapies into personalized treatment protocols that address each patient’s specific pathology. A typical inpatient program may include:
- Comprehensive diagnostic evaluation (mitochondrial markers, immune panels, hormonal assessment, viral serology)
- IHHT sessions for mitochondrial rehabilitation
- NAD+ and nutrient infusions
- Ozone therapy (MAH)
- Therapeutic apheresis (when indicated by lab findings)
- Neurofeedback for cognitive and sleep symptoms
- Hormonal optimization based on testing
- Nutritional and lifestyle medicine guidance
Frequently Asked Questions
Is there a cure for ME/CFS in 2025?
There is no single cure for ME/CFS as of 2025. However, significant progress has been made in understanding the disease mechanisms, and several therapies — both established and investigational — can produce meaningful improvement in symptoms and functional capacity. Many patients treated with comprehensive, root-cause-targeted protocols achieve substantial recovery, even if complete resolution of all symptoms is not always possible.
What is BC007, and is it available?
BC007 is an investigational aptamer developed by Berliner Cures GmbH that neutralizes autoantibodies against G-protein-coupled receptors — a proposed driver of symptoms in a subset of ME/CFS and long COVID patients. As of 2025, BC007 is in Phase II clinical trials and is not yet commercially available. It represents a promising targeted approach, but results from larger trials are needed before definitive conclusions can be drawn.
How do I know which treatments are right for me?
ME/CFS is a heterogeneous condition — different patients have different underlying drivers. The first step is comprehensive diagnostic testing to identify which mechanisms are most active in your case (mitochondrial dysfunction, viral reactivation, autoimmune factors, hormonal imbalances, etc.). Treatment is then tailored to your specific findings. At St. George Hospital, this evaluation is the foundation of our approach.
Can I combine conventional and integrative treatments?
Yes, and this is often the most effective strategy. Many of our patients continue conventional medications (such as low-dose naltrexone or thyroid support) while adding integrative therapies like IHHT, NAD+ infusions, and ozone therapy. Dr. Julian Douwes and our medical team work with patients to develop protocols that integrate all relevant therapeutic options.
Explore Treatment Options at St. George Hospital
If you are living with ME/CFS and seeking access to the latest evidence-based and integrative therapies, we welcome your inquiry. Our chronic fatigue program combines decades of clinical experience with the most current research insights.
Contact us:
Phone: +49 (0)8061 398-0
Email: info@clinicum-stgeorg.de
Request a consultation
This article is for informational purposes only. Investigational therapies discussed here are not approved standard treatments and should be considered in consultation with a qualified physician. Individual results vary.
]]>